<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271088</url>
  </required_header>
  <id_info>
    <org_study_id>EUTF 2010/32</org_study_id>
    <nct_id>NCT01271088</nct_id>
  </id_info>
  <brief_title>Protective Effect of N-acetylcysteine Against From Ototoxicity</brief_title>
  <official_title>Phase 3 Study of Protective Effect of N-acetylcysteine Against From Ototoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal
      dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis
      despite their potential risk for ototoxicity. NAC is a molecule used in the treatment and
      prophylaxis of many diseases related to oxidative stress. The aim of this study was to
      examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can
      be prevented by N-acetylcysteine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAC, a thiol-containing antioxidant because of this,we want to investigate antioxidant
      status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Threshold hearing levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Ototoxicity was defined as an increase in the auditory threshold by at least 20 dB at any one test frequency, or at least 10 dB at any two adjacent frequencies, or loss of response at three consecutive frequencies between the baseline and follow-up studies in the worse ear.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hearing Loss, Extreme</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Vancomycine and/or amikacin alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage renal disease

          -  Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy

          -  Developing the first continuous ambulatory peritoneal dialysis related peritonitis
             episode

        Exclusion Criteria:

          -  Being treated with aminoglycoside antibiotics and vancomycine within the previous 3
             months

          -  Detection of mechanical occlusion of external ear

          -  Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry

          -  History of a continuous ambulatory peritoneal dialysis related peritonitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismail Kocyigit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erciyes University</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>November 15, 2011</last_update_submitted>
  <last_update_submitted_qc>November 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Ismail Kocyigit</investigator_full_name>
    <investigator_title>TC Erciyes University Department of Nephrology</investigator_title>
  </responsible_party>
  <keyword>ototoxicity</keyword>
  <keyword>aminoglycoside</keyword>
  <keyword>vancomycine</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>peritonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

